4//SEC Filing
Sachs David C. 4
Accession 0001848899-26-000001
CIK 0001326110other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 6:11 PM ET
Size
426.3 KB
Accession
0001848899-26-000001
Insider Transaction Report
Form 4
Sachs David C.
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-31+30,397→ 256,017 total - Tax Payment
Common Stock
2025-12-31$1.98/sh−15,435$30,561→ 240,582 total - Exercise/Conversion
Restricted Stock Units
2025-12-31−30,397→ 45,602 total→ Common Stock (30,397 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
- [F2]On December 31, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 30, 2025 was the settlement price used to calculate the shares withheld.
- [F3]17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.
Issuer
ImmunityBio, Inc.
CIK 0001326110
Entity typeother
Related Parties
1- filerCIK 0001848899
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 6:11 PM ET
- Size
- 426.3 KB